Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 1,901–2,000 of 4,275
RNA binding proteins in senescence: A potential common linker for age-related diseases?
Varesi, A., Campagnoli, L. I. M., Barbieri, A., Rossi, L., Ricevuti, G., Esposito, C., Chirumbolo, S., Marchesi, N., & Pascale, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101958 · Cited by 29
MRE11 and TREX1 control senescence by coordinating replication stress and interferon signaling
Técher, H., Gopaul, D., Heuzé, J., Bouzalmad, N., Leray, B., Vernet, A., Mettling, C., Moreaux, J., Pasero, P., & Lin, Y. (2024) · Nature Communications · doi:10.1038/s41467-024-49740-w · Cited by 36
“Volcano plots showed increased expression of IFN, ISG and SASP genes in BJ-RAS V12 cells compared to control BJ cells (Fig.”
InfluentialThe role of lamin B receptor in the regulation of senescence-associated secretory phenotype (SASP)
En, A., Takauji, Y., Ayusawa, D., & Fujii, M. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.111927 · Cited by 30
Apigenin and Rutaecarpine reduce the burden of cellular senescence in bone marrow stromal stem cells
Ali, D., Okla, M., Abuelreich, S., Vishnubalaji, R., Ditzel, N., Hamam, R., Kowal, J. M., Sayed, A., Aldahmash, A. M., Alajez, N. M., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1360054 · Cited by 29
Chauhan, S., Jaiswal, S., Jakhmola, V., Singh, B. P., Bhattacharya, S., Garg, M., & Sengupta, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216766 · Cited by 32
Patel, Z. S., Grugan, K. D., Rustgi, A. K., Cucinotta, F. A., & Huff, J. L. (2012) · Radiation Research · doi:10.1667/rr2790.1 · Cited by 32
“This enhanced secretory phenotype supports epithelial tumor growth and is observed both in vitro and in vivo (43).”
BackgroundSenolytics: charting a new course or enhancing existing anti-tumor therapies?
Czajkowski, K., Herbet, M., Murias, M., & Piątkowska‐Chmiel, I. (2024) · Cellular Oncology · doi:10.1007/s13402-024-01018-5 · Cited by 40
Thorin‐Trescases, N., Labbé, P., Mury, P., Lambert, M., & Thorin, É. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212232 · Cited by 31
“Using transcriptomic or proteomic approaches, successive studies of the secretome of senescent cells of different cell types and with various senescence inducers added progressively new members to the SASP [12,76,84,85].”
BackgroundMethodInfluentialIs early life adversity a trigger towards inflammageing?
Merz, M. P., & Turner, J. D. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111377 · Cited by 31
Two Functionally Distinct Isoforms of TL1A (TNFSF15) Generated by Differential Ectodomain Shedding
Mück, C., Herndler‐Brandstetter, D., Mičutková, L., Grubeck‐Loebenstein, B., & Jansen‐Dürr, P. (2010) · The Journals of Gerontology Series A · doi:10.1093/gerona/glq129 · Cited by 28
The Intricate Interplay between Mechanisms Underlying Aging and Cancer
Piano, A., & Titorenko, V. I. (2014) · Aging and Disease · doi:10.14336/ad.2014.0209 · Cited by 30
Major depression, physical health and molecular senescence markers abnormalities
Seitz‐Holland, J., Mulsant, B. H., Reynolds, C. F., Blumberger, D. M., Karp, J. F., Butters, M. A., Mendes‐Silva, A. P., Vieira, É. L. M., Tseng, G. C., Lenze, E. J., et al. (2023) · Nature Mental Health · doi:10.1038/s44220-023-00033-z · Cited by 32
“Statistical analyses were performed using IBM SPSS Statistics 27 and GraphPad Prism 9.”
MethodDNA damage-dependent mechanisms of ageing and disease in the macro- and microvasculature
Shah, A. V., & Bennett, M. R. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.03.050 · Cited by 28
Crescenzi, E., Raia, Z., Pacifico, F., Mellone, S., Moscato, F., Palumbo, G. A., & Leonardi, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.435149 · Cited by 31
“Forced expression of 16220 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288 • NUMBER 23 • JUNE 7, 2013 Wip1 suppresses DDR and induces inappropriate re-initiation ofmitosis, asdemonstratedbyanalysesofhistoneH3phosphorylation.”
BackgroundInfluentialThe role of p21 in regulating mammalian regeneration
Arthur, L. M., & Heber‐Katz, E. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt71 · Cited by 35
Cell senescence: basic mechanisms and the need for computational networks in vascular ageing
Regnault, V., Challande, P., Pinet, F., Li, Z., & Lacolley, P. J. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa318 · Cited by 28
Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer’s Disease
Fülöp, T., Tripathi, S., Rodrigues, S., Desroches, M., Bunt, T., Eiser, A. R., Bernier, F., Beauregard, P. B., Barron, A. E., Khalil, A., et al. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s264910 · Cited by 27
SPINKs in Tumors: Potential Therapeutic Targets
Liao, C., Wang, Q., An, J., Zhang, M., Chen, J., Li, X., Xiao, L., Wang, J., Long, Q., Liu, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.833741 · Cited by 39
“Clinical radiotherapy and chemotherapy remove tumors by removing rapidly expanding malignant cells, but their off-target effects often cause irreparable damage to benign stromal cells and lead to typical cellular senescence (62).”
BackgroundGiunta, S., Wei, Y., Xu, K., & Xia, S. (2022) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13686 · Cited by 27
“Most components of the SASP are upregulated at the level of messenger RNA (mRNA) abundance.(12) Moreover, the increase in mRNA levels of many factors depends on the transcription factors nuclear factor κB (NF-κB) and C/EBPβ, which have increased activity in senescent cells.”
BackgroundThe footprint of the ageing stroma in older patients with breast cancer
Brouwers, B. A. H., Fumagalli, D., Brohée, S., Hatse, S., Govaere, O., Floris, G., den Eynde, K. V., Barèche, Y., Schöffski, P., Smeets, A., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0871-0 · Cited by 28
“In this process, a major role has been attributed to matrix metalloproteinase 3 [23] together with other components of the SASP [25, 26], such as inflammatory cytokines and chemokines.”
BackgroundTherapy-induced senescent tumor cells in cancer relapse
Song, K., Wang, J., & Huang, D. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.09.001 · Cited by 57
“41 In addition, IL-6 and IL-8 have been shown to modulate STAT3 activation.”
BackgroundRaynard, C., Ma, X., Huna, A., Tessier, N., Massemin, A., Zhu, K., Flaman, J., Moulin, F., Goehrig, D., Médard, J., et al. (2022) · Aging Cell · doi:10.1111/acel.13632 · Cited by 26
“…of some specific features, including an enhanced senescence- associated- βgalactosidase (SA- β- gal) activity (Dimri et al., 1995) and the secretion of numerous factors, named senescence- associated secretory phenotype or SASP (Acosta et al., 2008; Coppé et al., 2008; Kuilman et al., 2008).”
BackgroundThe Expression of the Senescence-Associated Biomarker Lamin B1 in Human Breast Cancer
Saleh, T., Alhesa, A., El‐Sadoni, M., Shahin, N. A., Alsharaiah, E., Shboul, S. A., Awad, H., Bloukh, S., Al-Balas, M., Alsalem, M., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12030609 · Cited by 30
“The senescent phenotype is complex and encompasses a variety of hallmarks including structural changes [7], metabolic dysregulation [8], increased lysosomal biogenesis (marked by the upregulation of the senescence-associated beta-galactosidase, SA-β-gal) [9,10], epigenetic signatures [11], and wide alterations in gene…”
Backgroundc-Myb and C/EBPβ regulate OPN and other senescence-associated secretory phenotype factors
Flanagan, K. C., Alspach, E., Pazolli, E., Parajuli, S. P., Ren, Q., Arthur, L., TAPIA-CONYER, R. C., & Stewart, S. A. (2017) · Oncotarget · doi:10.18632/oncotarget.22940 · Cited by 31
Sun, Y., Li, X., Yang, X., Chen, B., & Zhang, W. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9955448 · Cited by 29
“Senescent NPCs showed impaired proliferation and the balance of ECM synthesis, especially a persistent proinflammatory phenotype called SASP, which influences the cellular microenvironment in a paracrine or autocrine manner [22, 23].”
BackgroundSelf-citationKotla, S., Le, N., Vu, H. T., Ko, K. A., Gi, Y. J., Thomas, T. N., Giancursio, C. J., Lusis, A. J., Cooke, J. P., Fujiwara, K., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153962 · Cited by 29
Vanvalkenburg, A., Kaipilyawar, V., Sarkar, S., Lakshminarayanan, S., Cintron, C., Babu, S. P., Knudsen, S., Joseph, N. M., Horsburgh, C. R., Sinha, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011166 · Cited by 45
“Median age, years (range) 13 (9-35) 37 (12-80) 26.”
BackgroundInfluentialCirculating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes
Sabbatinelli, J., Matacchione, G., Giuliani, A., Ramini, D., Rippo, M. R., Procopio, A. D., Bonafè, M., & Olivieri, F. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111667 · Cited by 30
Haraoka, Y., Akieda, Y., Nagai, Y., Mogi, C., & Ishitani, T. (2022) · Nature Communications · doi:10.1038/s41467-022-29061-6 · Cited by 28
Toro, N. D., Ruiz, A. F., Mignacca, L., Kalegari, P., Rowell, M., Igelmann, S., Saint‐Germain, E., Benfdil, M., Lopes‐Paciencia, S., Brakier‐Gingras, L., et al. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1593708 · Cited by 34
“Senescent cells are characterized as nonproliferative with a high rate of proteins synthesis and defects in ribosome biogenesis [16,30,31].”
BackgroundATM-Mediated DNA Damage Signals Mediate Immune Escape through Integrin-αvβ3–Dependent Mechanisms
Jinushi, M., Chiba, S., Baghdadi, M., Kinoshita, I., Dosaka‐Akita, H., Ito, K., Yoshiyama, H., Yagita∥, H., Uede, T., & Takaoka, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2028 · Cited by 29
Interleukin-6 at the Host-Tumor Interface: STAT3 in Biomolecular Condensates in Cancer Cells
Sehgal, P. B. (2022) · Cells · doi:10.3390/cells11071164 · Cited by 29
“, macrophages) has been implicated as part of the senescence-associated secretory phenotype (SASP) [35,36].”
BackgroundThe female reproduction and senescence nexus
Marquez, C. M., Ibana, J. A., & Velarde, M. C. (2017) · American Journal of Reproductive Immunology · doi:10.1111/aji.12646 · Cited by 30
Vassilieva, I. O., Reshetnikova, G., Shatrova, A. N., Tsupkina, N. V., Харченко, М. В., Lp, A., Nikolsky, N. N., & Burova, E. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.163 · Cited by 31
Georgakilas, A. G., Redon, C. E., Ferguson, N. F., Kryston, T. B., Parekh, P. R., Dickey, J. S., Nakamura, A., Mitchell, J. B., Bonner, W. M., & Martin, O. A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.030 · Cited by 26
Methyl-CpG Binding Protein 2 in Alzheimer Dementia
Kim, B., Choi, Y., Kim, H.-S., & Im, H. (2019) · International Neurourology Journal · doi:10.5213/inj.1938196.098 · Cited by 35
“Interestingly, the SASP converts senescent brain cells into a pro-inflammatory phenotype that releases cytokines, chemokines, proteases, and growth factors [14], which in turn can activate neighboring microglia and astrocytes to give rise to reactive glia.”
BackgroundYang, J., Jiang, Q., Liu, L., Peng, H., Wang, Y., Li, S., Tang, Y., Yu, J., Gan, R., & Liu, Z. (2020) · Aging · doi:10.18632/aging.104199 · Cited by 32
Novel Perspectives in Chronic Kidney Disease-Specific Cardiovascular Disease
Xu, C., Tsihlis, G., Chau, K., Trinh, K., Rogers, N. M., & Julovi, S. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052658 · Cited by 33
“Senescent cells remain metabolically active and acquire a secretory phenotype (denoted SASP), characterized by the production of pro-inflammatory cytokines [131], ligands of the Wnt– β -catenin pathway [132,133], and TGF-β [134].”
BackgroundM(o)TOR of aging: MTOR as a universal molecular hypothalamus
Blagosklonny, M. V. (2013) · Aging · doi:10.18632/aging.100580 · Cited by 29
“Thus, proinflammatory and hypersecretory phenotypes are hallmarks of senescence [23-32].”
BackgroundWang, J., Zhou, X., Yu, P., Yao, J., Guo, P., Xu, Q., Zhao, Y., Wang, G., Li, Q., Zhu, X., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00886-2 · Cited by 28
Culibrk, R. A., & Hahn, M. S. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.583884 · Cited by 32
“, 2016), inflammatory cytokines, including IL-6 and IL-8, are highly conserved in SASPs and are believed to play a crucial role in maintaining SASP signaling and senescence (Acosta et al., 2008; Coppé et al., 2008; Lasry and Ben-Neriah, 2015).”
BackgroundMolecular Mechanisms to Target Cellular Senescence in Hepatocellular Carcinoma
Mittermeier, C., Konopa, A., & Muehlich, S. (2020) · Cells · doi:10.3390/cells9122540 · Cited by 30
The inflammatory network: bridging senescent stroma and epithelial tumorigenesis
Shan, W., Yang, G. S., & Liu, J. (2009) · Frontiers in bioscience · doi:10.2741/3511 · Cited by 32
“Novel discoveries presented by this work is that SASP induced epithelialmesenchymal transition (EMT) as well as promoted migratoriness of epithelial (including tumor) cells (91), features commonly seen in more invasive epithelial cancer cells.”
BackgroundInfluentialLafferty-Whyte, K., Bilsland, A., Cairney, C. J., Hanley, L., Jamieson, N. B., Zaffaroni, N., Oien, K. A., Burns, S., Roffey, J., Boyd, S. M., et al. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-532 · Cited by 26
“In this study we used a DNA damage associated senescence (DAS) signature and a modified secretory senescence (mSS) signature compiled from recent data on senescence associated gene expression [11,12,14-23] to probe publicly available tumour gene expression data sets and our own mesenchymal tumour set using a scoring a…”
BackgroundMethodDyslipidemia Exacerbates Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis
Tomioka, Y., Kitazawa, K., Yamashita, Y., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062131 · Cited by 26
“Senescent cells acquire a complex, often pro-inflammatory, secretory phenotype termed the senescence-associated secretory phenotype (SASP) [67], which can change the neighboring microenvironment, such as by lipid-induced inflammation.”
BackgroundDoes Nrf2 Play a Role of a Master Regulator of Mammalian Aging?
Zinovkin, R. A., Kondratenko, N. D., & Zinovkina, L. A. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922120045 · Cited by 32
Mannarino, M., Martinez, O. W., Sheng, K., Li, L., Navarro-Ramírez, R., Jarzem, P. F., Ouellet, J. A., Cherif, H., & Haglund, L. (2023) · Biomolecules · doi:10.3390/biom13081257 · Cited by 29
“The senescence-associated secretory phenotype (SASP) refers to the secretion of cytokines, chemokines, neurotrophins, growth factors, and proteases by senescent cells [10,11].”
BackgroundThe dual function of cGAS-STING signaling axis in liver diseases
Li, X., Qu, J., Zhang, Y.-H., & Liu, R. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01220-5 · Cited by 29
“This process leads to an increase in the secretion of in fl ammatory cytokines, chemokines, and growth factors, and contributes to the of tumorigenesis and disease progression, the phenotype of which is termed the senescence-associated secretory phenotype (SASP) [90].”
Chronological Age Affects MSC Senescence In Vitro—A Systematic Review
Kapetanos, K., Asimakopoulos, D., Christodoulou, N., Vogt, A., & Khan, W. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157945 · Cited by 31
“It is an irreversible state that protects a cell from the consequences of compromised genomic integrity [44].”
BackgroundDNA damage response and GATA4 signaling in cellular senescence and aging-related pathology
Xiong, H., Hua, F., Dong, Y., Lin, Y., Ying, J., Liu, J., Wang, X., Zhang, L., & Zhang, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.933015 · Cited by 28
“Judith Campisi and her team found that aging cells induced by genotoxic stress secreted many substances related to inflammation and carcinogenesis, and this phenotype was defined as senescenceassociated secretory phenotype (SASP) (Coppe et al., 2008).”
BackgroundSudhir, P., Chen, C., Kumari, M. P., Wang, M.-J., Tsou, C., Sung, T., Chen, C., & Chen, C. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.020875 · Cited by 26
Oxaloacetate decarboxylase FAHD1 – a new regulator of mitochondrial function and senescence
Etemad, S., Petit, M., Weiss, A. K. H., Schrattenholz, A. S., Baraldo, G., & Jansen‐Dürr, P. (2018) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2018.07.007 · Cited by 28
Chromosomal instability and pro-inflammatory response in aging
Barroso‐Vilares, M., & Logarinho, E. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.111118 · Cited by 28
The PCa Tumor Microenvironment
Sottnik, J. L., Zhang, J., Macoska, J. A., & Keller, E. T. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0073-8 · Cited by 31
“In another study, it was shown that senescent fibroblasts derived from lung, foreskin or breast tissues, or prostate stromal fibroblasts forced to undergo senescence, secreted significantly higher levels of many of these same cytokines and chemokines collectively termed ‘senescence associated secreted proteins’ (SASPs…”
BackgroundArrested development and the great escape – The role of cellular senescence in pancreatic cancer
Moir, J. A. G., White, S. A., & Mann, J. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.10.018 · Cited by 28
Safwan‐Zaiter, H., Wagner, N., Michiels, J., & Wagner, K. (2022) · Cells · doi:10.3390/cells11030541 · Cited by 28
Bao, C., Wang, X.-T., Ma, W., Wang, N., Nesa, E. U., Wang, J., Wang, C., Jia, Y., Wang, K., Tian, H., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.001 · Cited by 26
The molecular mechanism of aging and the role in neurodegenerative diseases
Zhao, J.-L., Han, Z.-J., Ding, L., Wang, P., He, X.-T., & Lin, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24751 · Cited by 33
“Senescent cells undergo metabolic reprogramming, chromatin remodeling, and morphological alterations before secreting a complex concoction of mostly inflammatory chemicals known as the SASP [71].”
BackgroundMenicacci, B., Margheri, F., Laurenzana, A., Chillà, A., Rosso, M. D., Giovannelli, L., Fibbi, G., & Mocali, A. (2018) · The Journals of Gerontology Series A · doi:10.1093/gerona/gly175 · Cited by 32
Never-ageing cellular senescence
Öğrünç, M., & di Fagagna, F. D. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.003 · Cited by 37
Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function
Sandri, B. J., Masvidal, L., Murie, C., Bartish, M., Avdulov, S. V., Higgins, L., Markowski, T. W., Peterson, M., Bergh, J. C. S., Yang, P., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201801-0080oc · Cited by 26
Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner
Etxebeste-Mitxeltorena, M., del Rincón-Loza, I., & Martín-Antonio, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717850 · Cited by 28
Chen, C., Chen, J., Wang, W., Xie, L., Shao, C.-Q., & Zhang, Y. (2020) · Orthopaedic Surgery · doi:10.1111/os.12886 · Cited by 26
A NRF2-induced secretory phenotype activates immune surveillance to remove irreparably damaged cells
Baird, L., Taguchi, K., Zhang, A., Takahashi, Y., Suzuki, T., Kensler, T. W., & Yamamoto, M. P. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102845 · Cited by 29
Autophagy and PTEN in DNA damage-induced senescence
Sharma, A., & Almasan, A. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.01.006 · Cited by 29
The dual role of cellular senescence in human tumor progression and therapy
Ma, L., Yu, J., Fu, Y., He, X., Ge, S., Jia, R., Zhuang, A., Yang, Z. H., & Fan, X. (2024) · MedComm · doi:10.1002/mco2.695 · Cited by 33
The Two Faces of NF-κB Signaling in Cancer Development and Therapy
Klein, U., & Ghosh, S. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.026 · Cited by 29
Genetic Mosaicism and Cancer: Cause and Effect
Lichtenstein, A. V. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2769 · Cited by 24
Crowe, E. P., Sell, C., Thomas, J. D., Johannes, G. J., & Torres, C. A. (2009) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2009.10.005 · Cited by 26
“…senescent cells are known to increase with age in vivo (Herbig et al., 2006) and it has been suggested that these cells can influence the local tissue environment (Coppe et al., 2008), we examined both the level of oxidized proteins and the response to IGF-I in latepassage WI38 human fibroblasts.”
BackgroundIncorporating Biomarkers of Frailty and Senescence in Cancer Therapeutic Trials
Hubbard, J. M., & Jatoi, A. (2014) · The Journals of Gerontology Series A · doi:10.1093/gerona/glu046 · Cited by 25
“While the direct link with cellular senescence and the aging process has not been definitely established, research with progeroid mouse models demonstrated expression of SASP components such as IL-6, insulin-like growth factor-binding protein-2, and plasminogen activator inhibitor-1 are higher in senescent cells in fa…”
BackgroundInfluentialDNA damage-induced degradation of Sp1 promotes cellular senescence
Swift, M. L., Sell, C., & Azizkhan‐Clifford, J. (2021) · GeroScience · doi:10.1007/s11357-021-00456-5 · Cited by 28
Revisiting Epithelial Carcinogenesis
Méndez-López, L. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137437 · Cited by 30
“In turn, this protein coordinates the secretion of cytokines, chemokines, growth factors, and proteases liberated by senescent cells [15,116].”
BackgroundModeling of the immune response in the pathogenesis of solid tumors and its prognostic significance
Zadka, Ł., Grybowski, D. J., & Dzięgiel, P. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00519-3 · Cited by 30
“Apart from having a proinflammatory effect, paracrine release of SASP factors such as IL-6 and IL-8 may induce ep i the l i a l mesenchyme transition (EMT) and lead to cancer cell invasion [173].”
BackgroundDNA damage response in peritumoral regions of oesophageal cancer microenvironment
He, H., Tian, D., Guo, J., Liu, M., Chen, Z., Hamdy, F. C., Helleday, T., Su, M., & Ying, S. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs301 · Cited by 23
The Myc/macrophage tango: Oncogene-induced senescence, Myc style
Lee, S., Schmitt, C. A., & Reimann, M. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.10.002 · Cited by 31
Dao, M. A., Tate, C. C., Aizman, I., McGrogan, M. P., & Case, C. C. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-133 · Cited by 29
“As noted above, some studies have highlighted the pro-inflammatory secretome of senescent cells [8-10].”
BackgroundInfluentialSenescent Cells in Cancer: Wanted or Unwanted Citizens
Niklander, S. E., Lambert, D., & Hunter, K. D. (2021) · Cells · doi:10.3390/cells10123315 · Cited by 28
Tissue factor links inflammation, thrombosis, and senescence in COVID-19
Nguyen, D., Jeon, H.-M., & Lee, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-23950-y · Cited by 26
Abdelgawad, I. Y., Agostinucci, K. J., Ismail, S. G., Grant, M. K. O., & Zordoky, B. N. M. (2022) · Cells · doi:10.3390/cells11131992 · Cited by 32
“The senescence-associated secretory phenotype (SASP) is another important characteristic of senescent cells that encompasses multiple factors, including inflammatory cytokines, chemokines, growth factors, and extracellular matrix proteins [38].”
BackgroundOncogene-Induced Senescence and its Role in Tumor Suppression
Reddy, J. P., & Li, Y. (2011) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-011-9221-5 · Cited by 29
“Similarly, biopsies from patients with cancers of the lung, prostate, and breast who have undergone chemotherapy displayed evidence of senescence [44, 89, 92].”
BackgroundGiordani, C., Silvestrini, A., Giuliani, A., Olivieri, F., & Rippo, M. R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.734976 · Cited by 26
Senescence and odontoblastic differentiation of dental pulp cells
Nozu, A., Hamano, S., Tomokiyo, A., Hasegawa, D., Sugii, H., Yoshida, S., Mitarai, H., Taniguchi, S., Wada, N., & Maeda, H. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26905 · Cited by 27
“Senescent cells secrete higher levels of proteins with a senescence‐associated secretory phenotype, such as interleukin‐6, TNF‐α, matrix metalloproteinases, monocyte chemoattractant protein‐1, and insulin‐like growth factor–binding proteins, in multiple tissues with age (Coppe et al., 2008).”
BackgroundA GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells
Patel, R. S., Romero, R., Watson, E. V., Liang, A. C. T., Burger, M. L., Westcott, P. M. K., Mercer, K. L., Bronson, R. T., Wooten, E. C., Bhutkar, A. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27731-5 · Cited by 27
HDAC2 and 7 down-regulation induces senescence in dermal fibroblasts
Warnon, C., Bouhjar, K., Ninane, N., Verhoyen, M., Fattaccioli, A., Fransolet, M., Lambert de Rouvroit, C., Poumay, Y., Piel, G., Mottet, D., et al. (2021) · Aging · doi:10.18632/aging.203304 · Cited by 25
The aging of the immune system and its implications for transplantation
McGovern, K. E., Sonar, S. A., Watanabe, M., Coplen, C. P., Bradshaw, C. M., & Nikolich‐Žugich, J. (2023) · GeroScience · doi:10.1007/s11357-022-00720-2 · Cited by 27
Mapping cellular senescence networks in human diabetic foot ulcers
Yu, G., Monie, D. D., Khosla, S., Tchkonia, T., Kirkland, J. L., & Wyles, S. P. (2023) · GeroScience · doi:10.1007/s11357-023-00854-x · Cited by 27
“However, other studies have shown that absence of p53, the protein encoded by TP53 , was associated with a markedly increased SASP, which was consistent with our findings [51].”
Melanocytic Nevi and the Genetic and Epigenetic Control of Oncogene-Induced Senescence
Huang, J. M., Chikeka, I., & Hornyak, T. J. (2016) · Dermatologic Clinics · doi:10.1016/j.det.2016.08.001 · Cited by 38
“Finally, a senescence-activated secretory phenotype, which is marked by an increased expression of secreted proteins, including cytokines, is activated.(26) In addition to these cell-wide changes, several changes are also apparent on the molecular level in senescent cells.”
BackgroundKang, D., Jung, S. H., Lee, G., Lee, S., Park, H. J., Ko, Y., Kim, Y.-N., & Lee, J. (2020) · The FASEB Journal · doi:10.1096/fj.201902714r · Cited by 25
Xiao, Y., Liang, J., Witwer, K. W., Zhang, Y., Wang, Q., & Yin, H. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.955175 · Cited by 36
“Factors involved in SASP drive the systemic, lowgrade, chronic inflammation that accompanies human aging (4).”
BackgroundInfluentialTsaalbi‐Shtylik, A., Verspuy, J. W. A., Jansen, J. G., Rebel, H. G., Carlée, L., van der Valk, M. A., Jonkers, J., de Gruijl, F. R., & de Wind, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909507106 · Cited by 28
“However, IL-6 can also mediate the induction of inflammatory hyperplasia, which is associated with pathological phenotypes, including the stimulation of carcinogenesis (1, 17, 18, 30, 33, 34).”
BackgroundInfluentialOncogene‐induced senescence and melanoma: where do we stand?
Peeper, D. S. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00933.x · Cited by 31
“Exceptions include a number of secreted factors, including cytokines and chemokines (Acosta et al., 2008; Coppé et al., 2008; Kuilman et al., 2008; Wajapeyee et al., 2008; Ye et al., 2007), which are regulated during, and appear to play a role in the mechanism of, senescence in vitro and in vivo.”
BackgroundRapamycin induces pluripotent genes associated with avoidance of replicative senescence
Pospelova, T. V., Bykova, T. V., Zubova, S. G., Katolikova, N. V., Yartzeva, N. M., & Pospelov, V. A. (2013) · Cell Cycle · doi:10.4161/cc.27396 · Cited by 29
“Despite the cell cycle block, protein translation continues, cells accumulate various intracellular and secreted proteins and cytokines, creating a so-called “senescenceassociated secretory phenotype”, or SASP.(13,105,106) The abundant protein synthesis is ensured by the high activity of the mTOR signaling pathway (mT…”
BackgroundLee, S. H., Yang, J.-H., Park, U., Choi, H., Kim, Y. S., Yoon, B., Han, H.-J., Kim, H.-T., Um, S., & Kim, E.-J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01012-1 · Cited by 36
“Taken together, these results indicate that pinosylvin prevents bleomycin-induced pulmonary senescence by increasing the levels of SIRT1 and its activator AROS while decreasing that of Cdh1, a SIRT1 destabilizer.”
Greenberg, E. F., Voorbach, M. J., Smith, A. G., Reuter, D. R., Zhuang, Y., Wang, J.-Q., Wooten, D., Asque, E., Hu, M., Hoft, C., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36483 · Cited by 34
“…manufacturer ’ s protocol (Fluidigm ref 68000133 D2) with the following gene targets: p16, p21, IL-6 and TNF α were as previously described [25], IL-1 β , IL-8 and MCP-1 were as previously described [39,40], ACTB forward 5 ′ - CACCATTGGCAATGAGCGGTTC -3 ′ , reverse 5 ′ - AGGTCTTTGCGGATGTCCACGT-3 ′ .”
MethodPawelec, G. (2017) · Biogerontology · doi:10.1007/s10522-017-9739-z · Cited by 25
Jiang, J., Hu, H., Chen, Q., Zhang, Y., Chen, W., Huang, Q., Chen, X., Li, J., & Zhong, M. (2020) · Placenta · doi:10.1016/j.placenta.2020.10.009 · Cited by 29
Okamura, K., Sato, M., Suzuki, T., & Nohara, K. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116231 · Cited by 27
Novel ARF/p53-independent senescence pathways in cancer repression
Chan, C., Gao, Y., Moten, A., & Lin, H. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0766-y · Cited by 29
“For instance, it was shown that senescent cells may acquire a senescence-associated secretory phenotype, which empowers senescent cells to secrete proinflammatory interleukins, growth factors, and protein/extracellular components, which may stimulate the malignant phenotype of neighboring cells [125, 126].”
BackgroundLee, H. J., Choi, B., Kim, Y., Lee, S. E., Jin, H. J., Lee, H.-S., Chang, E., & Kim, S. W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01659 · Cited by 30
“SASP entails the secretion of proinflammatory cytokines, chemokines, growth factors, and extracellular matrix remodeling proteases (9, 10).”
Background
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.